Biomerica Inc (BMRA)vsBoston Scientific Corp (BSX)
BMRA
Biomerica Inc
$1.70
-1.73%
HEALTHCARE · Cap: $7.91M
BSX
Boston Scientific Corp
$43.50
-1.85%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 485608% more annual revenue ($21.07B vs $4.34M). BSX leads profitability with a 16.6% profit margin vs -115.5%. BSX earns a higher WallStSmart Score of 62/100 (C+).
BMRA
Avoid23
out of 100
Grade: F
BSX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMRA.
Margin of Safety
-7.2%
Fair Value
$39.17
Current Price
$43.50
$4.33 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Price/Book.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while BSX is a value play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.57 — expect wider price swings.
BSX is growing revenue faster at 1.4% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (62/100 vs 23/100), backed by strong 16.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
Visit Website →Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?